Risperidone-induced weight gain and reduced locomotor activity in juvenile female rats: The role of histaminergic and NPY pathways

Pharmacological Research : the Official Journal of the Italian Pharmacological Society
Jiamei LianChao Deng

Abstract

Second generation antipsychotic drugs (SGAs) such as risperidone are increasingly prescribed (mostly for off-label use) to children and adolescents for treating various mental disorders. SGAs cause serious weight gain/obesity and other metabolic side-effects. This study aimed to establish an animal model of risperidone-induced weight gain in female juvenile rats, and to investigate the effects of risperidone on the expression of hypothalamic histaminergic H1 receptors (H1R) and neuropeptides, and their association with weight gain. Female Sprague Dawley rats were treated orally with risperidone (0.3mg/kg, 3 times/day) or vehicle (control) starting from postnatal day (PD) 23 (±1 day) for 3 weeks (a period corresponding to the childhood-adolescent period in humans). In the female juvenile rats, risperidone treatment increased food intake and body weight gain, which started to appear after 12 days' treatment. Risperidone also significantly decreased the locomotor activity of the female rats. Consistently, risperidone significantly elevated mRNA expression of hypothalamic H1R, neuropeptide Y (NPY), and agouti-related peptide (AgRP) compared to controls, and H1R and NPY levels were correlated with risperidone enhanced weight gain an...Continue Reading

References

Aug 6, 1999·Journal of the American Academy of Child and Adolescent Psychiatry·J A FrazierS Shapiro
Jan 5, 2001·European Child & Adolescent Psychiatry·H RemschmidtE Schulz
Feb 24, 2001·Journal of Child and Adolescent Psychopharmacology·A MartinJ F Leckman
Sep 10, 2002·Journal of the American Academy of Child and Adolescent Psychiatry·Richard SnyderUNKNOWN Risperidone Conduct Study Group
Oct 9, 2002·Clinical and Experimental Pharmacology & Physiology·Miyuki OtaAkira Ota
Dec 31, 2002·Journal of Psychopharmacology·Andrew J GoudieJason C G Halford
Feb 28, 2003·The Journal of Pharmacology and Experimental Therapeutics·Shitij KapurJose N Nobrega
Mar 12, 2003·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Wesley K KroezeBryan L Roth
Jan 18, 2006·Neuroendocrinology·E A JørgensenA Kjaer
May 16, 2006·Behavioural Brain Research·Tim KarlIrina Dedova
Oct 31, 2006·Journal of Child and Adolescent Psychopharmacology·Joan LubyEdward Spitznagel
Mar 16, 2007·Proceedings of the National Academy of Sciences of the United States of America·Sangwon F KimSolomon H Snyder
Oct 16, 2007·European Journal of Pharmacology·Jenny L Wiley
Dec 29, 2007·Neuroscience Letters·Sarah L PooleSusan A Deuchars
Jul 9, 2008·Australasian Psychiatry : Bulletin of Royal Australian and New Zealand College of Psychiatrists·Garry WalterJoseph Rey
Dec 17, 2008·Physiology & Behavior·Mark B CopeTim R Nagy
Mar 19, 2009·World Psychiatry : Official Journal of the World Psychiatric Association (WPA)·Marc DE HertRuud VAN Winkel
Apr 15, 2009·Journal of Child and Adolescent Psychopharmacology·Chadi A CalargeJanet A Schlechte
Nov 20, 2009·Progress in Neuro-psychopharmacology & Biological Psychiatry·Chao DengXu-Feng Huang
Mar 11, 2010·Journal of the American Academy of Child and Adolescent Psychiatry·Mark OlfsonTobias Gerhard
Jun 24, 2010·Pharmacology, Biochemistry, and Behavior·S S EversA J W Scheurink
Jul 22, 2010·European Psychiatry : the Journal of the Association of European Psychiatrists·C U Correll
Nov 9, 2010·Behavioural Brain Research·Katrina Weston-GreenChao Deng
Nov 11, 2010·Current Medicinal Chemistry·T Masaki, H Yoshimatsu
Dec 30, 2010·The Annals of Pharmacotherapy·Ryan K OwenbyJamie N Brown
Jan 29, 2011·The Journal of Clinical Psychiatry·Christoph U Correll
Mar 23, 2011·Current Opinion in Pharmacology·H Y Meltzer, B W Massey
May 10, 2011·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Alessandro ZuddasTatiana Usala
Sep 2, 2011·Journal of Clinical Psychopharmacology·Howard DembKeith Thomas Ayoob
Dec 15, 2011·Journal of Child and Adolescent Psychopharmacology·Lawrence Maayan, Christoph U Correll

❮ Previous
Next ❯

Citations

Nov 24, 2016·International Journal of Molecular Sciences·Michael De SantisChao Deng
Dec 7, 2017·Frontiers in Neuroscience·Jiezhong ChenChao Deng
Jun 3, 2016·Psychopharmacology·Louise BenarrochMargaret K Hahn
Jul 15, 2016·Journal of Psychopharmacology·Aung Aung Kywe MoeDarryl W Eyles
Jan 21, 2020·Journal of Neuroendocrinology·Tássia Karin Ferreira BorbaRaul Manhães-de-Castro
Aug 15, 2017·Frontiers in Neuroscience·Zachary FreybergJacob S Ballon

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic-Induced Weight Gain

Antipsychotic-induced weight gain (aiwg) is a common adverse effect of this treatment, particularly with second-generation antipsychotics, and it is a major health problem around the world. Here are the latest discoveries pertaining to AIWG.

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here